Curiox Biosystems KRX:445680KOSDAQ
큐리옥스바이오시스템즈 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days1
DART filings, 7 days4
Articles tracked1since Sep 11
In Q2 2026, Curiox Biosystems reported revenue of ₩1.2bn, up 18.1% year on year, and an operating loss of ₩4.5bn. Curiox Biosystems (큐리옥스바이오시스템즈) appeared in 1 Korean news article and 4 DART filings over the past seven days. Coverage peaked on Oct 6 with 1 article. The most common catalyst was contracts & orders (1).
Filing signals 4 quarters of losses Screener
Curiox Biosystems quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩1.2bn | +18.1% | −₩4.5bn | −₩4.8bn |
| Q1 2026 | ₩1.3bn | +43.7% | −₩3.3bn margin −245.5% | −₩2.6bn |
| Q4 2025 derived | ₩1.8bn | +93.5% | −₩2.7bn margin −143.4% | −₩2.3bn |
| Q3 2025 | ₩1.4bn | +45.5% | −₩2.7bn margin −193.6% | −₩3.0bn |
| Q2 2025 | ₩996m | -8.9% | −₩4.0bn | −₩18.3bn |
| Q1 2025 | ₩922m | -41.9% | −₩3.0bn | −₩3.6bn |
| Q4 2024 derived | ₩956m | -59.1% | −₩3.6bn | ₩1.7bn |
| Q3 2024 | ₩951m | +39.6% | −₩3.3bn | −₩4.0bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Curiox Biosystems top stories 2 weeks, by number of outlets
- 1